Foley JE - Search Results

1

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea.

Garber AJ, Foley JE, Banerji MA, Ebeling P, Gudbjörnsdottir S, Camisasca RP, Couturier A, Baron MA. Garber AJ, et al. Among authors: foley je. Diabetes Obes Metab. 2008 Nov;10(11):1047-56. doi: 10.1111/j.1463-1326.2008.00859.x. Epub 2008 Feb 18. Diabetes Obes Metab. 2008. PMID: 18284434 Clinical Trial.

2

Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database.

Pratley RE, Schweizer A, Rosenstock J, Foley JE, Banerji MA, Pi-Sunyer FX, Mills D, Dejager S. Pratley RE, et al. Among authors: foley je. Diabetes Obes Metab. 2008 Sep;10(10):931-8. doi: 10.1111/j.1463-1326.2007.00835.x. Epub 2007 Dec 17. Diabetes Obes Metab. 2008. PMID: 18093207

3

An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials.

Ligueros-Saylan M, Foley JE, Schweizer A, Couturier A, Kothny W. Ligueros-Saylan M, et al. Among authors: foley je. Diabetes Obes Metab. 2010 Jun;12(6):495-509. doi: 10.1111/j.1463-1326.2010.01214.x. Diabetes Obes Metab. 2010. PMID: 20518805

4

Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.

Rosenstock J, Foley JE, Rendell M, Landin-Olsson M, Holst JJ, Deacon CF, Rochotte E, Baron MA. Rosenstock J, et al. Among authors: foley je. Diabetes Care. 2008 Jan;31(1):30-5. doi: 10.2337/dc07-1616. Epub 2007 Oct 18. Diabetes Care. 2008. PMID: 17947341 Clinical Trial.

5

Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes.

Schweizer A, Couturier A, Foley JE, Dejager S. Schweizer A, et al. Among authors: foley je. Diabet Med. 2007 Sep;24(9):955-61. doi: 10.1111/j.1464-5491.2007.02191.x. Epub 2007 May 17. Diabet Med. 2007. PMID: 17509069 Clinical Trial.

6

Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population.

Schweizer A, Dejager S, Foley JE, Couturier A, Ligueros-Saylan M, Kothny W. Schweizer A, et al. Among authors: foley je. Diabetes Obes Metab. 2010 Jun;12(6):485-94. doi: 10.1111/j.1463-1326.2010.01215.x. Diabetes Obes Metab. 2010. PMID: 20518804

7

Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study.

Matthews DR, Dejager S, Ahren B, Fonseca V, Ferrannini E, Couturier A, Foley JE, Zinman B. Matthews DR, et al. Among authors: foley je. Diabetes Obes Metab. 2010 Sep;12(9):780-9. doi: 10.1111/j.1463-1326.2010.01233.x. Diabetes Obes Metab. 2010. PMID: 20649630 Clinical Trial.

8

Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes.

Horton ES, Foley JE, Shen SG, Baron MA. Horton ES, et al. Among authors: foley je. Curr Med Res Opin. 2004 Jun;20(6):883-9. doi: 10.1185/030079903125003881. Curr Med Res Opin. 2004. PMID: 15200747 Clinical Trial.

9

Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia.

Scherbaum WA, Schweizer A, Mari A, Nilsson PM, Lalanne G, Wang Y, Dunning BE, Foley JE. Scherbaum WA, et al. Among authors: foley je. Diabetes Obes Metab. 2008 Nov;10(11):1114-24. doi: 10.1111/j.1463-1326.2008.00875.x. Epub 2008 Mar 18. Diabetes Obes Metab. 2008. PMID: 18355325 Clinical Trial.

10

Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response.

Ristic S, Byiers S, Foley J, Holmes D. Ristic S, et al. Diabetes Obes Metab. 2005 Nov;7(6):692-8. doi: 10.1111/j.1463-1326.2005.00539.x. Diabetes Obes Metab. 2005. PMID: 16219012 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

346 results

Search Page